-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma reports early activity for alrizomadlin in pediatric solid tumor trial at ASCO 2026

PUBT·05/31/2026 23:30:27
Listen to the news
Ascentage Pharma reports early activity for alrizomadlin in pediatric solid tumor trial at ASCO 2026
  • Ascentage Pharma presented first pediatric solid-tumor data for alrizomadlin (APG-115) at the 2026 ASCO Annual Meeting.
  • The early-stage China trial showed initial tumor responses in relapsed or metastatic sarcomas, including complete remissions in monotherapy or combination use.
  • Adding lisaftoclax (APG-2575) appeared to broaden activity across several pediatric tumor types, supporting a dual-target development strategy.
  • Tolerability looked manageable, with no dose-limiting toxicities reported, helping de-risk continued clinical development in children.
  • Alrizomadlin’s inclusion in China’s SPARK pediatric oncology program reinforces its strategic positioning for pediatric expansion despite no US FDA approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605311930PRIMZONEFULLFEED9729352) on May 31, 2026, and is solely responsible for the information contained therein.